Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.

Lancet (London, England) ·Vol. 354 ·No. 9190 ·1999-11-06 ·Pages 1610

Poulter NR, Chang CL, Farley TM, Meirik O

Abstract

Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.

MeSH Terms

Adult Case-Control Studies Contraceptives, Oral, Synthetic/adverse effects Female Humans Logistic Models Middle Aged Myocardial Infarction/chemically induced Odds Ratio Progesterone Congeners/adverse effects,therapeutic use Risk Factors Stroke/chemically induced Thromboembolism/chemically induced World Health Organization

Chemicals

Contraceptives, Oral, Synthetic Progesterone Congeners

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Poulter N R

Chang C L

Farley T M

Meirik O

Article Info

Journal

Lancet (London, England)

Abbr.

Lancet

ISSN

0140-6736

DOI

10.1016/s0140-6736(99)03132-3

Published

1999-11-06

Pages

1610

Language

English

Region

England

NLM ID

2985213R

Subset

Corrections

CommentOn

PMID: 7500748

CommentOn

PMID: 8757151

CommentOn

PMID: 8757152

CommentOn

PMID: 9130941

External Links

PubMed source DOI: 10.1016/s0140-6736(99)03132-3 View journal details

Analysis Services

Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.

Contact

WeChat Official Account